DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer
Neoplasm Metastasis

Interventions: Drug: Cetuximab

First Posted Date: 2005-08-16

Last Posted Date: 2015-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT00130689

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

Phase 2

Completed

Conditions: Nonmalignant Neoplasm
Tuberous Sclerosis
Lymphangioleimyomatosis
Kidney Angiomyolipoma

Interventions: Drug: Rapamycin

First Posted Date: 2005-08-04

Last Posted Date: 2022-04-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT00126672

Locations: 🇺🇸
New York University Medical Center, New York, New York, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 4 locations

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Phase 2

Terminated

Conditions: Burkitt Lymphoma
Non-Hodgkins Lymphoma
Atypical Burkitt Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Methotrexate
Drug: Leucovorin
Drug: Cytarabine
Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna

First Posted Date: 2005-08-03

Last Posted Date: 2013-05-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00126191

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Tarceva and Capecitabine for Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer
Neoplasm Metastasis

First Posted Date: 2005-07-29

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00125021

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-07-26

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00123851

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

Phase 2

Completed

Conditions: Gallbladder Cancer
Biliary Tract Cancer

First Posted Date: 2005-07-26

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00123825

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Mitoxantrone
Drug: Rituximab
Drug: Zevalin

First Posted Date: 2005-07-14

Last Posted Date: 2014-04-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00119730

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin
MALT Lymphoma

Interventions: Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2005-07-04

Last Posted Date: 2016-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT00117156

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-06-30

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00116506

Locations: 🇺🇸
Massachusett General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Radiation: External Beam Radiotherapy
Drug: Flutamide (Eulexin) and Lupron or Zoladex

First Posted Date: 2005-06-28

Last Posted Date: 2022-01-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 206

Registration Number: NCT00116220

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy